Database→Davunetide

Tier 3NootropicNeuroprotectionCognitivePREMIUM

Davunetide

Davunetide (NAP / AL-108 / CP201) -- ADNP-Derived Octapeptide, Microtubule Stabilizer

No approved indication anywhere. No active IND in the United States as of 2026. ExoNavis Therapeutics (Tel Aviv) holds the current license for clinical development under the name CP201; development status is not publicly confirmed active. ALZFORUM lists Autism Spectrum Disorder as Phase 3 status but no active trial is registered on ClinicalTrials.gov as of early 2026. Not FDA-approved. Not EMA-approved. Not on WADA Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Davunetide (NAP, AL-108, CP201) is a synthetic octapeptide (NAPVSIPQ) derived from activity-dependent neuroprotective protein (ADNP). It promotes microtubule stability and inhibits tau hyperphosphorylation. The largest human trial, Boxer et al. (2014, Lancet Neurology), was a well-powered Phase 2/3 RCT in 313 PSP patients at 48 international centers that was fully negative on all primary, secondary, and exploratory endpoints. The trial authors concluded: davunetide is not an effective treatment for PSP. A Phase 2a MCI signal exists only as a conference abstract. Post-hoc sex-stratified re-analyses of the failed PSP trial, conducted by the compound's inventor, are hypothesis-generating only.

🔒

Full Profile: Premium Members Only

The complete Davunetide profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use